The FDA has provided traditional approval to pembrolizumab (Keytruda) plus trastuzumab, fluoropyrimidine-, and platinum-based chemotherapy for the initiation of treatment in adult patients with HER2-positive gastric or GEJ adenocarcinoma with PD-L1 expression (CPS ≥ 1). It was previously approved in May 2021, under accelerated approval, on the basis of interim results from the KEYNOTE-811 trial.
US pharma giant Eli Lilly has launched its highly anticipated diabetes and obesity drug, Mounjaro (tirzepatide), in India. The drug, available in 2.5 mg and 5 mg single-dose vials, is priced at ₹3,500 and ₹4,375, respectively. Since it is taken once a week, the monthly cost ranges from ₹14,000 to ₹17,500, significantly lower than the $1,000–$1,200 (₹86,000–1 lakh) price in the US.
The present study sought to establish how much type 2 diabetics manage their blood glucose and what influences their control. It was conducted at Dessie Hospital, Ethiopia, from February to March 2023 among 465 diabetic patients. The HbA1c test, which provides a long-term estimate of blood glucose levels, was used by the researchers rather than relying on fasting blood glucose alone.
The FUTURE-AI guidelines have been developed with the aim of improving the reliability, safety, and ethical aspects of artificial intelligence (AI) in healthcare. Although AI has revolutionized disease diagnosis and treatment prediction, many doctors and patients are wary of its use, mainly due to fears of bias, errors, and data privacy risks. To counter these, the FUTURE-AI Consortium of 117 experts from 50 countries has developed a set of recommendations that have been published in *BMJ*.
The American College of Physicians (ACP) has issued new guidelines to prevent episodic migraines among adults, specifically for primary care physicians who see patients who are not taking preventive migraine drugs previously.
